Osterborg 1996.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 148, multiple myeloma, Non‐Hodgkin lymphoma, chronic lymphocytic lymphoma; concomitant treatment: chemotherapy
Interventions	drug = Epoetin beta dose = a: 10000 IU sc 7x/week, b: titration hb‐target = 10‐14 g/dL (women), 10‐13 g/dL (men) planned ESA duration = 24 weeks
Outcomes	Primary: transfusion; secondary: safety, Hb
Notes	study number = 43680
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Low risk	central randomization